Summary
Medtronic plc announced the commencement of significant cash tender offers totaling up to $4.175 billion across various senior notes. These offers, conducted by its wholly-owned subsidiaries, are intended to refinance existing debt. The company anticipates these transactions will be leverage-neutral and expects a slight reduction in interest expense for fiscal year 2020, partially offset by increased U.S. taxes. The results of these tender offers, including the specific financial benefits, will not be fully determinable until early July 2019. Given that the transactions are expected to conclude late in Medtronic's first fiscal quarter of FY20, a material impact on Q1 FY20 financial results is not anticipated. Investors should monitor the outcome of these offers and their impact on the company's capital structure and future interest expenses.
Key Highlights
- 1Medtronic is launching tender offers for up to $4.175 billion in aggregate principal amount of its outstanding senior notes.
- 2The tender offers are being made by Medtronic's wholly-owned subsidiaries: Medtronic, Inc., Medtronic Global Holdings S.C.A., and Covidien International Finance S.A.
- 3The company expects the debt refinancing to be leverage-neutral.
- 4Medtronic anticipates lower interest expense in FY2020 as a result of these transactions, with a slight offset from increased U.S. taxes.
- 5The full financial impact and results of the tender offers will be determined after July 10, 2019.
- 6No material impact on Q1 FY20 financial results is expected due to the timing of the transactions.
- 7The tender offers are subject to a debt financing condition.